Nisha Joseph, MD

• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

  • Phase

    III
  • Conditions

    Relapsed or Refractory Multiple Myeloma (RRMM)
  • Location

    Winship Cancer Institute

• AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

  • Phase

    I/II
  • Conditions

    Multiple Myeloma
  • Location

    Winship Cancer Institute

• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  • Phase

    III
  • Conditions

    Relapsed or Refractory Multiple Myeloma
  • Location

    Winship Cancer Institute

• A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

  • Phase

    III
  • Conditions

    Relapsed or Refractory Multiple Myeloma
  • Location

    Emory University Hospital Midtown, Grady Health System, Winship Cancer Institute

• Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Phase

    II
  • Conditions

    Multiple Myeloma
  • Location

    Winship Cancer Institute

• Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  • Phase

    III
  • Conditions

    Multiple Myeloma
  • Location

    Winship Cancer Institute

• A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

  • Phase

    N/A
  • Conditions

    Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
  • Location

    Winship Cancer Institute

• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  • Phase

    I
  • Conditions

    Multiple Myeloma
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

  • Phase

    II
  • Conditions

    Smoldering Plasma Cell Myeloma
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  • Phase

    III
  • Conditions

    Smoldering Plasma Cell Myeloma
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

  • Phase

    I/II
  • Conditions

    Multiple Myeloma
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma.

Blood advances

Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.

NPJ vaccines

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

Blood cancer journal

How to rescue a DreaMM deferred ….

Med (New York, N.Y.)

Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.

Journal of clinical apheresis

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.

Blood cancer journal

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.

Research square

Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.

JCO oncology practice

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.

bioRxiv : the preprint server for biology

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.

The Journal of clinical investigation

Passenger pathogens on physicians.

American journal of infection control

Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.

Blood cancer discovery

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.

Blood cancer journal

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Venetoclax ex vivo functional profiling predicts improved progression-free survival.

Blood cancer journal

Establishment of a COVID-19 perinatal biorepository in a safety net population.

Journal of the National Medical Association

Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.

Pharmacotherapy

Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.

Transplantation and cellular therapy

Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

Blood cancer discovery

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.

Blood

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.

Blood cancer journal

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Cancer

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.

Cancer

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Cancer

03/30/2025

Very consistent and caring

03/28/2025

Excellent!

03/26/2025

Dr. Joseph showed a genuine concern for me and demonstrated an incredible understanding of my specific myeloma condition.

03/12/2025

Dr. Joseph continues to exceed all expectations. She is kind and courteous, professional and caring. 10/10

03/08/2025

Dr Joseph is the best. She always has my history in mind, listens intently, takes plenty of time, and answers all my questions.

02/19/2025

Dr. Joseph is very calming.

01/23/2025

She made me feel like a person not just a patient. It like I see you, I hear you.

12/04/2024

Dr Joseph took her time. Explained everything so my wife and I could understand. She's very Compassionate. She also Called my other doctor for me to coordinate care then called me about It. Also arranged for my therapy closer to my home so don't have to drive so far. She is the best.

11/13/2024

Great

11/08/2024

Very good

11/01/2024

Good

10/30/2024

Dr. Nisha Joseph Is always courteous, personable and professional and makes me feel as if I'm her only patient. Excellent over the 4+ years I've been her patient.

10/19/2024

Excellent experience.

10/18/2024

From my Initial visit, Dr. Joseph made me feel visible and displayed value for my input. She allowed me time to express my views and validated them providing me with options. On this follow-up, she was engaged, showing that she was Informed of my progress and was prepared to discuss them with me. Finally, she discussed her plan for my future care and several times advised me of the opportunity to contact her if I saw any changes In my condition or desired to have follow-up with her. Note that the procedure I had is fairly new FDA-approved and the future outcomes are not fully understood. I really appreciate her as my Myeloma specialist.

10/16/2024

All was good

09/25/2024

Dr. Joseph was very thorough and supportive throughout my cancer diagnosis and treatment.

09/13/2024

Dr. JOSEPH IS VERY CARING AND WELL INFORMED

09/11/2024

Dr. Joseph discussed my situation in terms that I could understand. She made suggestions for a second opinion that I really appreciated.

08/28/2024

Overall my visit was a very good experience.

08/17/2024

Dr. Joseph makes sure you are involved in the decision making. She has a very easy going but professional approach.

08/02/2024

Very good explaining my issue.

07/13/2024

I have always that Dr. Joseph listened to my which made me much happier with my car and treatment.

07/13/2024

Good

06/26/2024

The doctor was very thorough and left no room for additional questioning.I fill extremely comfortable because I am in the hands caring and competent doctor(s).I can not wait to get back to my old self again,without a doubt I am heading in that direction.

06/23/2024

Dr Joseph is always very thorough and patient.

06/19/2024

We enjoy seeing Dr Joseph but I wish she would follow up with our local oncologist. At least send him the results or make the call to me that was promised.

06/17/2024

Dr Joseph is very patient and thorough. She explained everything about my results and listened to my concerns and informed me about the plans for future monitoring to stay on top of this process.

05/10/2024

Everything has been very good

05/03/2024

Dr. Joseph was amazing

05/03/2024

Dr Nisha Joseph is o e of the best!

04/26/2024

Both the muse and Dr. Joseph were so attentive to my needs. Dr Joseph, in particular, was amazing knowing how sensitive my condition and concerns were.